Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01628354




Registration number
NCT01628354
Ethics application status
Date submitted
21/06/2012
Date registered
26/06/2012
Date last updated
28/06/2012

Titles & IDs
Public title
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
Scientific title
A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD.
Secondary ID [1] 0 0
RHG
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Choroidal Neovascularization 0 0
Retinal Pigment Epithelial Detachment 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Cardiovascular 0 0 0 0
Other cardiovascular diseases
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ranibizumab

Treatment: Drugs: Ranibizumab
All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of >5 letters or increase in retinal thickness of >100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean change from baseline in best corrected visual acuity
Timepoint [1] 0 0
12 months
Secondary outcome [1] 0 0
Mean change from baseline in retinal thickness
Timepoint [1] 0 0
12 months
Secondary outcome [2] 0 0
Mean number of ranibizumab injections required over 12 months
Timepoint [2] 0 0
12 months
Secondary outcome [3] 0 0
Ocular and systemic adverse events
Timepoint [3] 0 0
12 months

Eligibility
Key inclusion criteria
- Patients presenting with choroidal neovascular membrane secondary to causes other than
AMD or patients with Pigment epithelial detachments secondary to AMD where there is
demonstrated progression of the disease.

- Total lesion area < 12 disc areas.

- Total area of CNV within the lesion must be > 50% of total lesion area in the first
category of recruits, but not in those with PEDs.

- Best corrected visual acuity of 20/40 to 20/320 in the study eye.

- Willing and able to give informed consent
Minimum age
20 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior treatment in the study eye with, external-beam radiation therapy, subfoveal
focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy or other
anti VEGF treatments.

- History of submacular surgery or other surgical intervention in the study eye,
glaucoma filtration surgery, corneal transplant surgery,

- Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month
preceding baseline,

- Extracapsular extraction of cataract with phacoemulsification within three months
preceding baseline, or a history of post-operative complications within the last 12
months preceding baseline in the study eye (uveitis, cyclitis, etc.),

- History of uncontrolled glaucoma in the study eye (defined as intraocular pressure =
25 mmHg despite treatment with anti-glaucoma medication),

- Aphakia with absence of the posterior capsule in the study eye,

- Active intraocular inflammation (grade trace or above) in the study eye,

- Any active infection involving ocular adnexa including infectious conjunctivitis,
keratitis, scleritis, endophthalmitis, as well as idiopathic or autoimmune-associated
uveitis in either eye,

- Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole
(Stage 3 or 4) in the study eye,

- Presence of a retinal pigment epithelial tear involving the macula in the study eye,

- Subfoveal fibrosis or atrophy in the study eye.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2010
Sample size
Target
Accrual to date
Final
49
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Royal Victorian Eye and Ear Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3002 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
University of Melbourne
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The investigators hypothesize that it is safe and effective to treat patients with choroidal
neovascularisation (abnormal blood vessels growing under the retina) secondary to causes
other than age related macular degeneration (AMD) and pigment epithelial detachments
(blisters of fluid under the retina) secondary to AMD with ranibizumab (Lucentis).

These groups of patients have to date been excluded from the multicentre trials demonstrating
significant benefit of Ranibizumab in the treatment of AMD.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01628354
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Robyn H Guymer, PhD
Address 0 0
University of Melbourne
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01628354